201 related articles for article (PubMed ID: 21885816)
1. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Prowell TM; Blackford AL; Byrne C; Khouri NF; Dowsett M; Folkerd E; Tarpinian KS; Powers PP; Wright LA; Donehower MG; Jeter SC; Armstrong DK; Emens LA; Fetting JH; Wolff AC; Garrett-Mayer E; Skaar TC; Davidson NE; Stearns V
Cancer Prev Res (Phila); 2011 Dec; 4(12):1993-2001. PubMed ID: 21885816
[TBL] [Abstract][Full Text] [Related]
2. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Egawa C; Hirokaga K; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Mitsunobu M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):262-269. PubMed ID: 26411314
[TBL] [Abstract][Full Text] [Related]
5. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
6. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Cuzick J; Sestak I; Forbes JF; Dowsett M; Knox J; Cawthorn S; Saunders C; Roche N; Mansel RE; von Minckwitz G; Bonanni B; Palva T; Howell A;
Lancet; 2014 Mar; 383(9922):1041-8. PubMed ID: 24333009
[TBL] [Abstract][Full Text] [Related]
8. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
[TBL] [Abstract][Full Text] [Related]
9. Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Erkanli S; Kayaselcuk F; Kuscu E; Bolat F; Sakalli H; Haberal A
Breast; 2006 Aug; 15(4):558-61. PubMed ID: 16311034
[TBL] [Abstract][Full Text] [Related]
10. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
11. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Ingle JN; Kalari KR; Buzdar AU; Robson ME; Goetz MP; Desta Z; Barman P; Dudenkov TT; Northfelt DW; Perez EA; Flockhart DA; Williard CV; Wang L; Weinshilboum RM
Steroids; 2015 Jul; 99(Pt A):32-8. PubMed ID: 25163006
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Baum M; Budzar AU; Cuzick J; Forbes J; Houghton JH; Klijn JG; Sahmoud T;
Lancet; 2002 Jun; 359(9324):2131-9. PubMed ID: 12090977
[TBL] [Abstract][Full Text] [Related]
13. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
[TBL] [Abstract][Full Text] [Related]
14. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
[TBL] [Abstract][Full Text] [Related]
15. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
16. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Sanford M; Plosker GL
Drugs; 2008; 68(9):1319-40. PubMed ID: 18547136
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Lipsitz M; Delea TE; Guo A
Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
[TBL] [Abstract][Full Text] [Related]
18. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
Bender CM; Sereika SM; Brufsky AM; Ryan CM; Vogel VG; Rastogi P; Cohen SM; Casillo FE; Berga SL
Menopause; 2007; 14(6):995-8. PubMed ID: 17898668
[TBL] [Abstract][Full Text] [Related]
19. [Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
Lu HH; Li Q; Xu BH; Zhang P; Yuan P; Wang JY; Cai RG
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):520-5. PubMed ID: 22093630
[TBL] [Abstract][Full Text] [Related]
20. Primary hormone treatment in postmenopausal women with breast cancer.
Maciá Escalante S; Pons Sanz V; Rodríguez Lescure A; Ballester Navarro I; Carrato Mena A
Clin Transl Oncol; 2006 May; 8(5):372-4. PubMed ID: 16760014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
